Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to “Sell” at Zacks Investment Research

Zacks Investment Research downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a hold rating to a sell rating in a research note released on Friday, Zacks.com reports.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

A number of other brokerages have also recently weighed in on SUPN. Cowen set a $50.00 price target on shares of Supernus Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, August 7th. Stifel Nicolaus set a $55.00 price target on shares of Supernus Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, August 7th. Cantor Fitzgerald set a $60.00 price target on shares of Supernus Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, May 8th. Mizuho reaffirmed a buy rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, August 7th. Finally, BidaskClub raised shares of Supernus Pharmaceuticals from a hold rating to a buy rating in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. Supernus Pharmaceuticals presently has an average rating of Hold and an average price target of $54.43.

Shares of Supernus Pharmaceuticals stock opened at $27.51 on Friday. The company has a fifty day moving average price of $31.25 and a 200 day moving average price of $34.54. The company has a current ratio of 2.72, a quick ratio of 2.53 and a debt-to-equity ratio of 0.70. Supernus Pharmaceuticals has a twelve month low of $26.90 and a twelve month high of $51.38. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of 13.42, a price-to-earnings-growth ratio of 0.93 and a beta of 1.54.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.05. Supernus Pharmaceuticals had a net margin of 25.66% and a return on equity of 22.36%. The firm had revenue of $104.70 million during the quarter, compared to analysts’ expectations of $109.67 million. During the same period in the prior year, the company earned $0.57 EPS. The firm’s revenue was up 5.2% on a year-over-year basis. Analysts forecast that Supernus Pharmaceuticals will post 2.2 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Supernus Pharmaceuticals by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 5,345,217 shares of the specialty pharmaceutical company’s stock worth $176,873,000 after buying an additional 49,676 shares in the last quarter. Rice Hall James & Associates LLC lifted its holdings in Supernus Pharmaceuticals by 35.1% in the 2nd quarter. Rice Hall James & Associates LLC now owns 1,351,286 shares of the specialty pharmaceutical company’s stock worth $44,714,000 after buying an additional 350,905 shares in the last quarter. Neumeier Poma Investment Counsel LLC lifted its holdings in Supernus Pharmaceuticals by 1.1% in the 2nd quarter. Neumeier Poma Investment Counsel LLC now owns 957,401 shares of the specialty pharmaceutical company’s stock worth $31,680,000 after buying an additional 10,170 shares in the last quarter. Norges Bank acquired a new position in Supernus Pharmaceuticals in the 4th quarter worth $24,711,000. Finally, Acadian Asset Management LLC lifted its holdings in Supernus Pharmaceuticals by 1.3% in the 1st quarter. Acadian Asset Management LLC now owns 734,398 shares of the specialty pharmaceutical company’s stock worth $25,734,000 after buying an additional 9,364 shares in the last quarter. Hedge funds and other institutional investors own 98.93% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

See Also: Marijuana Stocks Investing Considerations

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.